CoDa Therapeutics Inc.

CoDa has demonstrated that modulating cellular gap junction communication represents a new paradigm in wound care - improving wound healing while managing inflammation and scarring.

CoDa has two open INDs on its patent-protected lead product candidate, Nexagon®, which dramatically improves the body's ability to repair damaged tissue and has broad applications. The technology has been shown to work in a variety of tissue types including eye, skin, brain, nerve, and spinal cord.

Nexagon® is conveniently applied topically, and is shown to be safe and  tolerable following administration to over 372 wounds on 156 subjects.

Founded on patented inventions and data generated in the laboratories in New Zealand and the UK, CoDa continues to develop a portfolio of novel, proprietary compounds.

Website: http://www.codatherapeutics.com/

The company profiled is one of the investment opportunities currently available in New Zealand. Please note that these opportunities are not endorsed or recommended by New Zealand Trade and Enterprise (NZTE) and may be updated from time to time. Investors are advised to contact our New Zealand-based Investment Specialist to discuss further and to conduct their own due diligence and independent advice on the relevant investment, before committing to any investment.